InvestSMART

Amplia Therapeutics Limited (ASX:ATX)

ALERT: Price-sensitive ASX Announcement for ATX
Current share price for ATX : $0.135 0.005 (3.85%)+
Announcement
Release
30 Jan 2026 8:28AM
Price at Release
$0.130
Full Release
download
Summary
Amplia Therapeutics Limited reported significant progress in its clinical trials and financial status for the quarter ending December 2025. The company concluded the quarter with a cash position of AUD 31.5 million, benefiting from AUD 3.8 million in government grants and tax incentives. Operating cash inflows reached AUD 2.4 million. Key clinical advancements included the successful continuation of the ACCENT trial which demonstrated enhanced chemotherapy effects with narmafotinib, achieving a 35% response rate in pancreatic cancer patients. Additionally, the AMPLICITY trial commenced, targeting dose optimization of narmafotinib combined with FOLFIRINOX. Regulatory achievements included positive FDA feedback and the granting of a key patent. Amplia also succeeded in listing on the US-based OTCQB Venture Market, expanding its investor outreach.
Key Points
  • Amplia ended the December 2025 quarter with AUD 31.5 million in cash.
  • Net operating cash inflows for the quarter were AUD 2.4 million.
  • Received AUD 3.8 million from government grants and tax incentives.
  • Operating outflows included AUD 0.9 million for staff and administration costs.
  • ACCENT trial showed a 35% response rate with narmafotinib.
  • AMPLICITY trial initiated to explore narmafotinib with FOLFIRINOX.
  • Positive FDA feedback on dosage optimization for narmafotinib.
  • Granted a key patent for narmafotinib.
  • Listed on the US-based OTCQB Venture Market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.